Andrew Salner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Salner has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Jamie S. Ostroff
Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications Helaine Bertsch
Department of Radiation Oncology, Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford, Connecticut
2 shared publications- Jacques Banchereau
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
2 shared publications - Karolina Palucka
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
2 shared publications - Michelle Price Judge
University of Connecticut
2 shared publications - Ming-Hui Chen
Department of Statistics University of Connecticut Storrs Connecticut USA
2 shared publications
Latest Publications
- 22 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6822)
Intron retention regulates STAT2 function and associates with immunotherapy response in lung cancer
Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for treating various diseases, including lung cancer. However, the molecular determinants of variable patient outcomes remain unclear. Using long-read RNA sequencing, we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified more than 149,000 full-length messenger RNA (mRNA) isoforms, more than half of which were unannotated and many that occurred in immune-related genes, particularly within the type I interferon response pathway. We functionally characterized retained introns in the STAT2 gene that produced altered protein isoforms that regulated immune signaling and interferon responses and correlated with patient survival after anti–programmed death-ligand 1 (PD-L1) immunotherapy. These findings position alternative splicing as a regulator of tumor immune responses and reveal intron retention in STAT2 as an interferon regulatory axis that correlates with PD-L1 checkpoint inhibitor response.
- 22 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6822)
Intron retention regulates STAT2 function and associates with immunotherapy response in lung cancer
Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for treating various diseases, including lung cancer. However, the molecular determinants of variable patient outcomes remain unclear. Using long-read RNA sequencing, we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified more than 149,000 full-length messenger RNA (mRNA) isoforms, more than half of which were unannotated and many that occurred in immune-related genes, particularly within the type I interferon response pathway. We functionally characterized retained introns in the STAT2 gene that produced altered protein isoforms that regulated immune signaling and interferon responses and correlated with patient survival after anti–programmed death-ligand 1 (PD-L1) immunotherapy. These findings position alternative splicing as a regulator of tumor immune responses and reveal intron retention in STAT2 as an interferon regulatory axis that correlates with PD-L1 checkpoint inhibitor response.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (12) , 1786-1799
Impact of an Electronic Patient-Reported Outcome–Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD)
PURPOSE: Post-treatment head and neck cancer (HNC) survivors experience multiple symptoms and behavioral health issues. We developed Head and Neck Survivorship Tool: Assessments and Recommendation (HN-STAR), a clinical decision support tool using electronic patient-reported outcomes (ePROs) to improve follow-up of HNC survivors. METHODS: We conducted a cluster-randomized controlled trial of oncology practices in the Wake Forest National Cancer Institute Community Oncology Research Program Research Base comparing HN-STAR to usual care (UC) during a routine clinic visit. Eligible survivors completed treatment for HNC < 2 years before. Before the visit, survivors completed ePROs rating the burden of 26 concerns (symptoms and health behaviors). During the visit, HN-STAR presented survivor's concerns and tailored clinician recommendations. After the visit, survivors reported which concerns were discussed. To evaluate differences in concerns discussed in clinic, concerns were characterized as absent or mild versus burdensome, with comparisons between arms for number of concerns discussed, number of burdensome concerns discussed, and proportion of burdensome concerns discussed, assessed by mixed models adjusted for within-practice correlation. RESULTS: Three hundred forty-nine survivors at 28 practices reported a previsit mean of 7.5 burdensome concerns (standard deviation, 4.6), most commonly xerostomia (70%), taste changes (53%), and neck or shoulder stiffness (48%). In adjusted models, survivors in the HN-STAR arm had more burdensome concerns discussed (4.1 v 3.3 concerns, P = .042) and a greater proportion of burdensome concerns discussed (57% v 44%, P = .015) at the visit than survivors in the UC arm. CONCLUSION: In a large, national, diverse, and symptomatic sample of HNC survivors at community oncology practices, using an ePRO-informed clinical decision support tool increased the likelihood that burdensome concerns were discussed in clinic. Alerting providers to burdensome concerns and presenting guideline-concordant management options at the point of care may improve provider-survivor interactions.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (12) , 1786-1799
Impact of an Electronic Patient-Reported Outcome–Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD)
PURPOSE: Post-treatment head and neck cancer (HNC) survivors experience multiple symptoms and behavioral health issues. We developed Head and Neck Survivorship Tool: Assessments and Recommendation (HN-STAR), a clinical decision support tool using electronic patient-reported outcomes (ePROs) to improve follow-up of HNC survivors. METHODS: We conducted a cluster-randomized controlled trial of oncology practices in the Wake Forest National Cancer Institute Community Oncology Research Program Research Base comparing HN-STAR to usual care (UC) during a routine clinic visit. Eligible survivors completed treatment for HNC < 2 years before. Before the visit, survivors completed ePROs rating the burden of 26 concerns (symptoms and health behaviors). During the visit, HN-STAR presented survivor's concerns and tailored clinician recommendations. After the visit, survivors reported which concerns were discussed. To evaluate differences in concerns discussed in clinic, concerns were characterized as absent or mild versus burdensome, with comparisons between arms for number of concerns discussed, number of burdensome concerns discussed, and proportion of burdensome concerns discussed, assessed by mixed models adjusted for within-practice correlation. RESULTS: Three hundred forty-nine survivors at 28 practices reported a previsit mean of 7.5 burdensome concerns (standard deviation, 4.6), most commonly xerostomia (70%), taste changes (53%), and neck or shoulder stiffness (48%). In adjusted models, survivors in the HN-STAR arm had more burdensome concerns discussed (4.1 v 3.3 concerns, P = .042) and a greater proportion of burdensome concerns discussed (57% v 44%, P = .015) at the visit than survivors in the UC arm. CONCLUSION: In a large, national, diverse, and symptomatic sample of HNC survivors at community oncology practices, using an ePRO-informed clinical decision support tool increased the likelihood that burdensome concerns were discussed in clinic. Alerting providers to burdensome concerns and presenting guideline-concordant management options at the point of care may improve provider-survivor interactions.
- 3 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1599-1607
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer
PURPOSE: Oncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease skeletal-related events for patients with metastatic castration-resistant prostate cancer (mCRPC) and against BMAs to decrease skeletal-related events in metastatic castration-sensitive prostate cancer (mCSPC). Previous studies have identified gaps in guideline-concordant BMA use, but interprovider variation is poorly understood. METHODS: We conducted a multicenter, retrospective, cohort study of patients diagnosed with prostate cancer and bone metastases during 2020-2021. The sample included three health systems in the Northeastern United States: two community-based networks and one academic cancer center. Patient characteristics and BMA use (zoledronic acid and denosumab) were ascertained via chart review. The outcomes of interest were BMA overuse during castration-sensitive prostate cancer (CSPC; defined as BMA initiation before emergence of castration-resistant prostate cancer [CRPC], among patients without a comorbid condition for which BMA therapy may be appropriate: osteoporosis, osteopenia, or osteoporotic fracture) and appropriate use during CRPC (BMA initiation after emergence of CRPC). RESULTS: There were 153 eligible patients, 51 from each health system. At diagnosis, 14 (9%) patients had documented osteoporosis or osteopenia, 22 (14%) had previous osteoporotic fracture, and 36 (24%) had chronic renal insufficiency. Among 95 patients assessable for overuse during CSPC, 16% (n = 17) received BMA (ranging from 13% to 21% among the three systems). Among 55 patients who developed CRPC, 44% (n = 24) had initiated BMA therapy as of most recent follow-up. There was greater variation in use during CRPC, ranging from 22% to 54% across the three systems. CONCLUSION: BMA overuse in mCSPC was rare, potentially reflecting de-implementation following evidence of lack of benefit. Appropriate BMA use for patients with mCRPC varies substantially among clinicians and health care systems. Interventions to increase guideline-concordant care may improve outcomes.
- 3 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1599-1607
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer
PURPOSE: Oncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease skeletal-related events for patients with metastatic castration-resistant prostate cancer (mCRPC) and against BMAs to decrease skeletal-related events in metastatic castration-sensitive prostate cancer (mCSPC). Previous studies have identified gaps in guideline-concordant BMA use, but interprovider variation is poorly understood. METHODS: We conducted a multicenter, retrospective, cohort study of patients diagnosed with prostate cancer and bone metastases during 2020-2021. The sample included three health systems in the Northeastern United States: two community-based networks and one academic cancer center. Patient characteristics and BMA use (zoledronic acid and denosumab) were ascertained via chart review. The outcomes of interest were BMA overuse during castration-sensitive prostate cancer (CSPC; defined as BMA initiation before emergence of castration-resistant prostate cancer [CRPC], among patients without a comorbid condition for which BMA therapy may be appropriate: osteoporosis, osteopenia, or osteoporotic fracture) and appropriate use during CRPC (BMA initiation after emergence of CRPC). RESULTS: There were 153 eligible patients, 51 from each health system. At diagnosis, 14 (9%) patients had documented osteoporosis or osteopenia, 22 (14%) had previous osteoporotic fracture, and 36 (24%) had chronic renal insufficiency. Among 95 patients assessable for overuse during CSPC, 16% (n = 17) received BMA (ranging from 13% to 21% among the three systems). Among 55 patients who developed CRPC, 44% (n = 24) had initiated BMA therapy as of most recent follow-up. There was greater variation in use during CRPC, ranging from 22% to 54% across the three systems. CONCLUSION: BMA overuse in mCSPC was rare, potentially reflecting de-implementation following evidence of lack of benefit. Appropriate BMA use for patients with mCRPC varies substantially among clinicians and health care systems. Interventions to increase guideline-concordant care may improve outcomes.
- Open Access
- 11 October 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (1) , 101917
Lutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer
- 11 October 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (1) , 101917
Open AccessLutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer
- Open Access
Intron retention regulates STAT2 function and predicts immunotherapy response in lung cancer
Immunotherapy benefits only a subset of lung cancer patients, and the molecular determinants of variable outcomes remain unclear. Using long-read RNA-sequencing we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified over 180,000 full-length mRNA isoforms, more than half of which were novel and many of which occurred in immune-related genes, particularly within the type I interferon response pathway. We discovered retained introns in the STAT2 gene that produce altered protein isoforms that regulate immune signaling and interferon responses. Furthermore, STAT2 intron retention levels predicted patient responses to checkpoint inhibitors. These findings position alternative splicing as a key regulator of tumor immune responses and reveal mRNA splicing alterations as potential biomarkers to identify patients who might respond to cancer immunotherapy.
Open AccessIntron retention regulates STAT2 function and predicts immunotherapy response in lung cancer
Immunotherapy benefits only a subset of lung cancer patients, and the molecular determinants of variable outcomes remain unclear. Using long-read RNA-sequencing we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified over 180,000 full-length mRNA isoforms, more than half of which were novel and many of which occurred in immune-related genes, particularly within the type I interferon response pathway. We discovered retained introns in the STAT2 gene that produce altered protein isoforms that regulate immune signaling and interferon responses. Furthermore, STAT2 intron retention levels predicted patient responses to checkpoint inhibitors. These findings position alternative splicing as a key regulator of tumor immune responses and reveal mRNA splicing alterations as potential biomarkers to identify patients who might respond to cancer immunotherapy.
- Open Access
- 18 July 2024
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 12 (1) , e53652
Acceptability, Effectiveness, and Roles of mHealth Applications in Supporting Cancer Pain Self-Management: Integrative Review
Background: Cancer pain remains highly prevalent and persistent throughout survivorship, and it is crucial to investigate the potential of leveraging the advanced features of mobile health (mHealth) apps to empower individuals to self-manage their pain. Objective: This review aims to comprehensively understand the acceptability, users’ experiences, and effectiveness of mHealth apps in supporting cancer pain self-management. Methods: We conducted an integrative review following Souza and Whittemore and Knafl’s 6 review processes. Literature was searched in PubMed, Scopus, CINAHL Plus with Full Text, PsycINFO, and Embase, from 2013 to 2023. Keywords including “cancer patients,” “pain,” “self-management,” “mHealth applications,” and relevant synonyms were used in the search. The Johns Hopkins research evidence appraisal tool was used to evaluate the quality of eligible studies. A narrative synthesis was conducted to analyze the extracted data. Results: A total of 20 studies were included, with the overall quality rated as high (n=15) to good (n=5). Using mHealth apps to monitor and manage pain was acceptable for most patients with cancer. The internal consistency of the mHealth in measuring pain was 0.96. The reported daily assessment or engagement rate ranged from 61.9% to 76.8%. All mHealth apps were designed for multimodal interventions. Participants generally had positive experiences using pain apps, rating them as enjoyable and user-friendly. In addition, 6 studies reported significant improvements in health outcomes, including enhancement in pain remission (severity and intensity), medication adherence, and a reduced frequency of breakthrough pain. The most frequently highlighted roles of mHealth apps included pain monitoring, tracking, reminders, education facilitation, and support coordination. Conclusions: mHealth apps are effective and acceptable in supporting pain self-management. They offer a promising multi-model approach for patients to monitor, track, and manage their pain. These findings provide evidence-based insights for leveraging mHealth apps to support cancer pain self-management. More high-quality studies are needed to examine the effectiveness of digital technology–based interventions for cancer pain self-management and to identify the facilitators and barriers to their implementation in real-world practice.
- 18 July 2024
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 12 (1) , e53652
Open AccessAcceptability, Effectiveness, and Roles of mHealth Applications in Supporting Cancer Pain Self-Management: Integrative Review
Background: Cancer pain remains highly prevalent and persistent throughout survivorship, and it is crucial to investigate the potential of leveraging the advanced features of mobile health (mHealth) apps to empower individuals to self-manage their pain. Objective: This review aims to comprehensively understand the acceptability, users’ experiences, and effectiveness of mHealth apps in supporting cancer pain self-management. Methods: We conducted an integrative review following Souza and Whittemore and Knafl’s 6 review processes. Literature was searched in PubMed, Scopus, CINAHL Plus with Full Text, PsycINFO, and Embase, from 2013 to 2023. Keywords including “cancer patients,” “pain,” “self-management,” “mHealth applications,” and relevant synonyms were used in the search. The Johns Hopkins research evidence appraisal tool was used to evaluate the quality of eligible studies. A narrative synthesis was conducted to analyze the extracted data. Results: A total of 20 studies were included, with the overall quality rated as high (n=15) to good (n=5). Using mHealth apps to monitor and manage pain was acceptable for most patients with cancer. The internal consistency of the mHealth in measuring pain was 0.96. The reported daily assessment or engagement rate ranged from 61.9% to 76.8%. All mHealth apps were designed for multimodal interventions. Participants generally had positive experiences using pain apps, rating them as enjoyable and user-friendly. In addition, 6 studies reported significant improvements in health outcomes, including enhancement in pain remission (severity and intensity), medication adherence, and a reduced frequency of breakthrough pain. The most frequently highlighted roles of mHealth apps included pain monitoring, tracking, reminders, education facilitation, and support coordination. Conclusions: mHealth apps are effective and acceptable in supporting pain self-management. They offer a promising multi-model approach for patients to monitor, track, and manage their pain. These findings provide evidence-based insights for leveraging mHealth apps to support cancer pain self-management. More high-quality studies are needed to examine the effectiveness of digital technology–based interventions for cancer pain self-management and to identify the facilitators and barriers to their implementation in real-world practice.
- 6 February 2024
- Published by Taylor & Francis in Pain Management
- Vol. 14 (2) , 40-53
Pain Management for Post-Treatment Survivors of Complex Cancers: A Qualitative Study of Opioids and Cannabis
Aim: We aimed to understand experiences with opioids and cannabis for post-treatment cancer survivors. Patients & methods: We conducted seven focus groups among head and neck and lung cancer surviv...
- 6 February 2024
- Published by Taylor & Francis in Pain Management
- Vol. 14 (2) , 40-53
Pain Management for Post-Treatment Survivors of Complex Cancers: A Qualitative Study of Opioids and Cannabis
Aim: We aimed to understand experiences with opioids and cannabis for post-treatment cancer survivors. Patients & methods: We conducted seven focus groups among head and neck and lung cancer surviv...
- Open Access
- 27 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Acceptability, Effectiveness, and Roles of mHealth Applications in Supporting Cancer Pain Self-Management: Integrative Review (Preprint)
BACKGROUND Cancer pain remains highly prevalent and persistent throughout survivorship, and it is crucial to investigate the potential of leveraging the advanced features of mobile health (mHealth) apps to empower individuals to self-manage their pain. OBJECTIVE This review aims to comprehensively understand the acceptability, users’ experiences, and effectiveness of mHealth apps in supporting cancer pain self-management. METHODS We conducted an integrative review following Souza and Whittemore and Knafl’s 6 review processes. Literature was searched in PubMed, Scopus, CINAHL Plus with Full Text, PsycINFO, and Embase, from 2013 to 2023. Keywords including “cancer patients,” “pain,” “self-management,” “mHealth applications,” and relevant synonyms were used in the search. The Johns Hopkins research evidence appraisal tool was used to evaluate the quality of eligible studies. A narrative synthesis was conducted to analyze the extracted data. RESULTS A total of 20 studies were included, with the overall quality rated as high (n=15) to good (n=5). Using mHealth apps to monitor and manage pain was acceptable for most patients with cancer. The internal consistency of the mHealth in measuring pain was 0.96. The reported daily assessment or engagement rate ranged from 61.9% to 76.8%. All mHealth apps were designed for multimodal interventions. Participants generally had positive experiences using pain apps, rating them as enjoyable and user-friendly. In addition, 6 studies reported significant improvements in health outcomes, including enhancement in pain remission (severity and intensity), medication adherence, and a reduced frequency of breakthrough pain. The most frequently highlighted roles of mHealth apps included pain monitoring, tracking, reminders, education facilitation, and support coordination. CONCLUSIONS mHealth apps are effective and acceptable in supporting pain self-management. They offer a promising multi-model approach for patients to monitor, track, and manage their pain. These findings provide evidence-based insights for leveraging mHealth apps to support cancer pain self-management. More high-quality studies are needed to examine the effectiveness of digital technology–based interventions for cancer pain self-management and to identify the facilitators and barriers to their implementation in real-world practice.
- 27 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAcceptability, Effectiveness, and Roles of mHealth Applications in Supporting Cancer Pain Self-Management: Integrative Review (Preprint)
BACKGROUND Cancer pain remains highly prevalent and persistent throughout survivorship, and it is crucial to investigate the potential of leveraging the advanced features of mobile health (mHealth) apps to empower individuals to self-manage their pain. OBJECTIVE This review aims to comprehensively understand the acceptability, users’ experiences, and effectiveness of mHealth apps in supporting cancer pain self-management. METHODS We conducted an integrative review following Souza and Whittemore and Knafl’s 6 review processes. Literature was searched in PubMed, Scopus, CINAHL Plus with Full Text, PsycINFO, and Embase, from 2013 to 2023. Keywords including “cancer patients,” “pain,” “self-management,” “mHealth applications,” and relevant synonyms were used in the search. The Johns Hopkins research evidence appraisal tool was used to evaluate the quality of eligible studies. A narrative synthesis was conducted to analyze the extracted data. RESULTS A total of 20 studies were included, with the overall quality rated as high (n=15) to good (n=5). Using mHealth apps to monitor and manage pain was acceptable for most patients with cancer. The internal consistency of the mHealth in measuring pain was 0.96. The reported daily assessment or engagement rate ranged from 61.9% to 76.8%. All mHealth apps were designed for multimodal interventions. Participants generally had positive experiences using pain apps, rating them as enjoyable and user-friendly. In addition, 6 studies reported significant improvements in health outcomes, including enhancement in pain remission (severity and intensity), medication adherence, and a reduced frequency of breakthrough pain. The most frequently highlighted roles of mHealth apps included pain monitoring, tracking, reminders, education facilitation, and support coordination. CONCLUSIONS mHealth apps are effective and acceptable in supporting pain self-management. They offer a promising multi-model approach for patients to monitor, track, and manage their pain. These findings provide evidence-based insights for leveraging mHealth apps to support cancer pain self-management. More high-quality studies are needed to examine the effectiveness of digital technology–based interventions for cancer pain self-management and to identify the facilitators and barriers to their implementation in real-world practice.
- 1 May 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (5) , e780-e785
Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis
PURPOSE: Community-academic partnerships have the potential to improve access to clinical trials for under-represented minority patients who more often receive cancer treatment in community settings. In 2017, the Memorial Sloan Kettering (MSK) Cancer Center began opening investigator-initiated clinical trials in radiation oncology in targeted community-based partner sites with a high potential to improve diverse population accrual. This study evaluates the effectiveness of a set of implementation strategies for increasing overall community-based enrollment and the resulting proportional enrollment of Hispanic patients on trials on the basis of availability in community-based partner sites. METHODS: An interrupted time series analysis evaluating implementation strategies was conducted from April 2018 to September 2021. Descriptive analysis ofHispanic enrollment on investigator-initiated randomized therapeutic radiation trials open at community-based sites was compared with those open only at themain academic center. RESULTS: Overall, 84 patients were enrolled in clinical trials in the MSK Alliance, of which 48 (56%) identified as Hispanic. The quarterly patient enrollment pre- vs postimplementation increased from 1.39 (95% CI, –3.67 to 6.46) to 9.42 (95% CI, 2.05 to 16.78; P5 .017). In the investigator-initiated randomized therapeutic radiation trials open in the MSK Alliance, Hispanic representation was 11.5% and 35.9% in twometastatic trials and 14.2% in a proton versus photon trial. Inmatched trials open only at the main academic center, Hispanic representation was 5.6%, 6.0%, and 4.0%, respectively. CONCLUSION: A combination of practice-level and physician-level strategies implemented at community-based partner sites was associated with increased clinical trial enrollment, which translated to improved Hispanic representation. This supports the role Q:2 of strategic community-academic partnerships in addressing disparities in clinical trial enrollment.
- 1 May 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (5) , e780-e785
Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis
PURPOSE: Community-academic partnerships have the potential to improve access to clinical trials for under-represented minority patients who more often receive cancer treatment in community settings. In 2017, the Memorial Sloan Kettering (MSK) Cancer Center began opening investigator-initiated clinical trials in radiation oncology in targeted community-based partner sites with a high potential to improve diverse population accrual. This study evaluates the effectiveness of a set of implementation strategies for increasing overall community-based enrollment and the resulting proportional enrollment of Hispanic patients on trials on the basis of availability in community-based partner sites. METHODS: An interrupted time series analysis evaluating implementation strategies was conducted from April 2018 to September 2021. Descriptive analysis ofHispanic enrollment on investigator-initiated randomized therapeutic radiation trials open at community-based sites was compared with those open only at themain academic center. RESULTS: Overall, 84 patients were enrolled in clinical trials in the MSK Alliance, of which 48 (56%) identified as Hispanic. The quarterly patient enrollment pre- vs postimplementation increased from 1.39 (95% CI, –3.67 to 6.46) to 9.42 (95% CI, 2.05 to 16.78; P5 .017). In the investigator-initiated randomized therapeutic radiation trials open in the MSK Alliance, Hispanic representation was 11.5% and 35.9% in twometastatic trials and 14.2% in a proton versus photon trial. Inmatched trials open only at the main academic center, Hispanic representation was 5.6%, 6.0%, and 4.0%, respectively. CONCLUSION: A combination of practice-level and physician-level strategies implemented at community-based partner sites was associated with increased clinical trial enrollment, which translated to improved Hispanic representation. This supports the role Q:2 of strategic community-academic partnerships in addressing disparities in clinical trial enrollment.
- Open Access
- 1 January 2021
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 6 (1) , 100623
Lutetium Lu-177 Dotatate Flare Reaction
- 1 January 2021
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 6 (1) , 100623
Open AccessLutetium Lu-177 Dotatate Flare Reaction